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We previously showed that intrathecal administration of methotrexate slowed disability
progression in multiple sclerosis (MS) patients with progressive disease. In general MS
patients with progressive disease respond poorly to anti-inflammatory therapies. In order
to better understand the mechanism by which methotrexate is protective in progressive
MS, we analyzed its impact on the non-inflammatory cuprizone-induced demyelination
model. When low-dose methotrexate was administered intracerebroventricularly it
reduced demyelination and accumulation of GFAP+ reactive astrocytes in the corpus
callosum. Administration of methotrexate after the withdrawal of cuprizone neither
delayed remyelination nor influenced the number of astrocytes in the corpus callosum
suggesting that methotrexate does not interfere with repair processes in the CNS.
Moreover, methotrexate increased the expression of IGF1 in vitro and in vivo, a factor
known to protect oligodendrocytes and limit the activation of astrocytes. Our studies show
that methotrexate has an impact on pathogenic process in a demyelination model whose
pathophysiological basis is not primarily related to inflammatory mechanisms, similar
to neurodegenerative mechanisms associated with progressive MS. The pronounced
inhibitory influence of methotrexate on the accumulation of astrocytes in the corpus
callosum suggests that intrathecal methotrexate modulates astroglial activation in
progressive MS possibly by promoting CNS production of IGF1.
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INTRODUCTION
Multiple sclerosis (MS) is characterized pathologically by
demyelination, axonal loss and glial scar formation. Clinically,
most patients have a relapsing-remitting course (RRMS) that over
time may become secondarily progressive (SPMS). About 15%
of patients have a progressive course from onset (PPMS). In the
past decade, several treatments have been approved by the Food
and Drug Administration (FDA) for use in RRMS and SPMS.
However, these therapies are not effective for PPMS and become
increasingly ineffective for SPMS especially in the degenerative
phase of the disease. Thus, more effective therapies need to be
developed for the progressive forms of MS (Hawker, 2011).
Methotrexate (MTX, amethopterin) is a folate analog that was
introduced in clinical practice more than 50 years ago. It com-
petitively inhibits dihydrofolate reductase (DHFR), an enzyme
that participates in folate metabolism and purine synthesis and
thereby MTX therapy results in inhibition of synthesis of ribonu-
cleic acids.
Abbreviations: CSF, cerebrospinal fluid; CC, corpus callosum; EAE, experimental
autoimmune encephalomyelitis; icv MTX, intracerebroventricular methotrexate;
ITMTX, intrathecal methotrexate.
MTX is an established chemotherapeutic agent and is also
widely used in the treatment of patients with psoriasis, rheuma-
toid arthritis and other autoimmune diseases. In MS, low dose
oral MTX (7.5mg weekly) is effective, although minimally, in
slowing deterioration in patients with SPMS (Goodkin et al.,
1995). Our center conducted a study using intrathecal methotrex-
ate administration (ITMTX) in 121 treatment unresponsive pro-
gressive MS patients with an initial EDSS score of more than 5.0
(Sadiq et al., 2010). ITMTX stabilized the disease course in 87%
of secondary-progressive and in 82% of primary progressive MS
patients within a two study period.
The mechanism of action of ITMTX in MS remains to be
elucidated. Chemotherapeutic immunosuppressive agents have
been extensively investigated in MS, but have limited efficacy in
progressive forms of MS (Kieseier and Jeffery, 2010). Profound
peripheral depletion of lymphocytes as a therapeutic strategy,
while highly effective in RRMS and inflammatory (relapsing)
forms of SPMS, has little or no benefit in late stage SPMS or
PPMS (Bradl and Lassmann, 2009). This may be because these
progressive forms of MS are pathologically in a degenerative and
non-inflammatory phase of the disease and are, therefore, unre-
sponsive to lymphocyte depletion (Bradl and Lassmann, 2009).
One of the pathologic hallmarks of the chronic stage of disease
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is glial proliferation and scarring (Moore et al., 2011), and it is
possible that ITMTX attenuates these aspects of the disease. An
alternate explanation for the efficacy trends seen with ITMTX
may be that some of the immune abnormalities seen in MS are
primarily CNS in origin and are, therefore, more responsive to
intrathecal therapy (Magliozzi et al., 2007). There is accumulat-
ing evidence that the inflammation seen in progressive MS is
trapped behind a closed or repaired blood brain barrier in pro-
gressive MS (Meinl et al., 2008). This view is also supported by
the observation that in progressive MS lymph follicle-like struc-
tures are formed with the connective tissue compartments within
the CNS, meninges, and large perivascular spaces (Bradl and
Lassmann, 2009). These CNS restricted immune responses may
be unaffected by systemic immunosuppression or by agents such
as natalizumab that stop lymphocyte trafficking across the blood
brain barrier. It is possible that ITMTX acts by limiting inflamma-
tory reactions in the CNS because of its route of administration
circumventing an intact blood brain barrier.
Feeding of cuprizone [bis(cyclohexanone)-oxaldihydrazone]
to mice induces a consistent, synchronous and anatomically
reproducible demyelination (Kipp et al., 2009). Importantly, the
pathology of this model is independent of adaptive immune
responses (Arnett et al., 2001). Furthermore, removal of cupri-
zone from the mice’s diet leads to remyelination (reviewed in
Matsushima and Morell, 2001). Cuprizone chelates copper, an
essential component of metalloenzymes, like the mitochondrial
cytochrome oxidase and monoamine oxidase (Acs and Komoly,
2012). It has been assumed although not proven that copper
deficiency results in specific damage to oligodendrocytes in the
CNS and subsequent demyelination. The specific susceptibility
of oligodendrocytes has been attributed to the high metabolic
demand of these glial cells required to maintain a vast expanse
of myelin and the resulting vulnerability to a disturbed energy
metabolism. This model allows analysis of demyelination in the
CNS accompanied by strong astrogliosis, without the interference
of the peripheral immune system (Matsushima andMorell, 2001).
To better understand the mechanisms of action of ITMTX on
progressive MS, we examined the effects of this therapy in the
cuprizone induced demyelination model.
MATERIALS AND METHODS
ANIMALS
C57Bl/6 mice, either 8 weeks or 1 year old, were purchased from
the Jackson Laboratory (Bar Harbor, ME). Animals were housed
in the animal facility of Roosevelt Hospital (New York, NY)
where our research center conducts its animal research. Food and
water were available ad libitum. All procedures were conducted
according to protocols approved by the Institutional Animal Care
and Use Committee (IACUC) of St. Luke’s Roosevelt Institute of
Health Sciences (New York City, NY).
INDUCTION OF DEMYELINATION
Demyelination was induced by feeding C57Bl/6 mice a diet
of 0.2% cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma-
Aldrich, St.Louis, MO) mixed into ground standard chow. The
ground chow supplemented with cuprizone was replaced every
other day.
EAE INDUCTION
Active EAE in female C57/B6 mice was induced by s.c.
immunization with 200µg MOG-peptide (aa 35–55:
MEVGWYRSPFSRVVHLYRNGK, Pepceuticals, UK) emul-
sified 1:1 in CFA containing 450µg H37Ra and i.p. injection of
200 ng pertussis toxin (Merck KGaA Germany) on days 0 and 2.
ADMINISTRATION OF METHOTREXATE
The Alzet Brain Infusion Kit 3 (DURECT Corp., Cupertino, CA)
and the Alzet osmotic pump (Alzet 1004, DURECT Corp.) were
used to deliver 0.5mg/mL methotrexate (MTX) dissolved in a
10mg/mL BrdU/PBS dilution or 10mg/mL BrdU/PBS (vehicle)
directly into the third ventricle. The osmotic pumps were con-
nected to the brain infusion cannula by catheter tubing 1 day
before surgery. The filled infusion assembly with attached osmotic
pump was incubated overnight in sterile saline at 37◦C. A group
size of eight animals was examined in all experiments.
For pump installation, mice were anesthetized with a mix-
ture of Ketamine (77mg/kg)/Xylazine (15mg/kg) in saline. The
animals were fixed in a stereotactic frame with non-traumatic ear-
bars to hold the skull in place. A small hole was created in the
skull with a drill bit. The coordinates of the hole for the can-
nula were 0.94mm posterior to the bregma, 0mm lateral, and
2.5mm ventral to the skull surface. The stereotactic arm hold-
ing the cannula was lowered into the third ventricle and glued to
the skull surface using veterinary skin adhesive (3M Vetbond, 3M
Animal Care Products, St. Paul, MN). Thereafter, the cannula was
covered by orthodontic powder mixed with acrylic resin liquid
(Lang Dental Manufacturing Inc., Wheeling, IL). Themini-pump
was inserted beneath the skin at the right scapula and the skin
was closed using surgical adhesive. The volume and the rate of
delivery of PBS or MTX by mini-pump were ∼100 nL per h con-
tinuously for 28 days. Mice received approximately 50µg MTX
per kg body weight and day mirroring the low dose intrathe-
cal MTX administration in progressive MS patients (Sadiq et al.,
2010). Mice were housed individually to avoid possible damage to
the mini-pump.
QUANTIFICATION OF DEMYELINATION, GLIAL ACTIVATION AND
ASTROGLIAL PROCESSES LENGTH
The amount of demyelination and accumulation of reactive astro-
cytes andmacrophages andmicroglial cells in the corpus callosum
were quantified by immunohistofluorescent analyses.
At the end of the experiment, mice were transcardially per-
fused with 4%PFA. The brains were removed, postfixed overnight
in PFA and embedded in paraffin. 5µm serial paraffin sections
representing the corpus callosum were cut, dried at 37◦C, de-
waxed, rehydrated and boiled for 5min in 10mM citrate buffer
(pH 6.0). Sections were quenched with H2O2, blocked with 1%
goat serum and incubated with primary antibodies for the detec-
tion of myelin, astrocytes and macrophages/ microglial cells.
Following primary antibodies were used: anti-BrdU (clone G3G4,
Development Studies Hybridoma-Bank, IA), polyclonal rat anti-
MBP (Millipore, MA), mouse anti-GFAP (clone G-A-5, Sigma
Aldrich) and rabbit anti-Iba1 (Thermo Scientific). Isotype con-
trol antibodies and staining without primary antibodies were
used as controls. Following secondary antibodies were used: Alexa
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Fluor 555 goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse
IgG1, Alexa Fluor 647 goat anti-mouse IgG2 and Alexa Fluor 647
goat anti-rat (all from Abcam).
In order to quantify the number of reactive astrocytes and of
macrophages/microglial cells in the corpus callosum, GFAP+ cells
as well as Iba1+ positive cells were counted by a blinded investi-
gator. At least twelve brain slices per mouse were analyzed. The
myelination of the corpus callosum was determined by calculat-
ing the ratio of the demyelinated area in the corpus callosum and
the total area of the corpus callosum.
The length of the astroglial processes was determined using
the Fiji software (Schindelin et al., 2012) based on GFAP staining
of corpus callosum containing brain sections. For every slide the
length of 20 representative astroglial processes was determined by
a blinded investigator. Six slides per mouse were analyzed.
CSF SAMPLES AND MICROARRAY PROCEDURE
Cerebrospinal fluid (CSF) was collected with informed con-
sent and approval (protocol number 05–178) from the St.
Luke’s-Roosevelt Hospital Center Institute for Health Sciences
Institutional Review Board (New York, NY) either via standard
lumbar puncture or by access port aspiration of an implanted
baclofen pump for the treatment of spasticity. CSF samples were
centrifuged and the cell-free supernatant was stored frozen at
−80◦C. RNA was isolated from pelleted CSF cells using the
RNeasy Micro Kit (Qiagen, Hilden, Germany).
RNA was processed and analyzed by microarray hybridization
by the Centre of Excellence for Fluorescent Bioanalytics (KFB,
Regensburg, Germany) as described before (Muller et al., 2012).
Probe set intensities; background correction and signal nor-
malization were done using the MAS 5.0 algorithm (Affymetrix).
Analyses were performed using BRB Array Tools version 4.1.0
(Simon et al., 2007). Signal intensities were normalized using the
array with the median overall signal intensities as reference. All
gene expression intensities below 10 were set to the value of 10.
Probe sets with less than 10% of expression data values having at
least 1.5-fold change in either direction from the gene’s median
value were excluded from further evaluations.
QUANTIFICATION OF IGF1 PROTEIN IN HUMAN CSF
IGF1 concentrations in cell-free CSF were measured using the
Human IGF1 ELISA development Kit, DuoSet (R&D Systems,
Minneapolis, MN). Measurements were performed in duplicates.
QUANTIFICATION OF IGF1 EXPRESSION IN CORPUS CALLOSUM
After 4 weeks of cuprizone feeding and icv MTX administra-
tion, mice were sacrificed and perfused via left cardiac ventri-
cle with RNAse-free phosphate buffered saline (PBS) for gene
expression analysis. A group size of eight animals was inves-
tigated. For gene expression analysis the brains were removed
and immediately embedded in O.C.T. TISSUE-Tek Compound
(Sacura, CA) and stored at −80◦C until use. Serial coro-
nal sections with a thickness of 10µm were cut at −20◦C.
The sections were mounted on PEN membrane slides (LEICA
GmbH, Germany) and prepared for microdissection using the
Histogene LCM Frozen Section Staining Kit (Life Technologies).
The LMD6000 laser microdissection microscope (Leica GmbH,
Germany) was used to excise the medial part of the corpus
callosum. The RNeasy Micro plus kit (Qiagen, Germany) was
used to isolate RNA immediately after microdissection. cDNA
was generated using the Sensiscript RT kit (Qiagen). The IGF1
expression was quantified using murine IGF1 specific Taqman
probes (Mm00439560_m1, Applied Biosystems) and normal-
ized to respective 18S rRNA quantities also determined by using
Taqman probes.
METHOTREXATE TREATMENT OF MOUSE EMBRYONIC-DERIVED
OLIGODENDROCYTES PRECURSOR CELLS (ES-OPCs) AND
QUANTIFICATION OF IGF1 EXPRESSION
We studied a highly pure batch of ES-OPCs, previously estab-
lished and characterized in our lab. To address the impact of
methotrexate on the ability of oligodendroglial cell to produce
IGF1, ES-OPCs (100,000 per well in a 24 well plate) were incu-
bated for 10 days in 2mL of N2 media without growth factors,
a condition known to promote terminal differentiation of these
cells into oligodendrocytes (Brustle et al., 1999), supplemented
with varying amounts of methotrexate. 25% of the medium was
changed every other day. The IGF1 expression was quantified
using murine IGF1 specific Taqman probes as described above for
microdissected tissue analysis.
STATISTICAL ANALYSES
Statistical analyses were performed using SigmaStat 3.0 (IBM,
Somers, NY). Comparisons of groups of normal-distributed data
were done by Student’s t-test or an ANOVA analysis.
RESULTS
INFLUENCE OF METHOTREXATE ON CUPRIZONE-INDUCED PATHOLOGY
IN THE CORPUS CALLOSUM
We aimed to investigate the effect of methotrexate administra-
tion on the cuprizone-induced demyelination mouse model that
is characterized by a highly reproducible demyelination of distinct
brain regions independent of an immune attack on the myelin
sheet (Kipp et al., 2009). Mice received methotrexate intracere-
broventricularly by osmotic pumps at a dosage of approximately
1.25µg per day. Methotrexate was reported before to be pro-
tective in the context of the inflammatory MS animal model
experimental autoimmune encephalomyelitis (EAE) (Rosenthale
et al., 1969). In order to confirm that the selected dosage of
1.25µg per day had an in vivo effect, we tested it within the con-
text of EAE. The administration started at the beginning of EAE
disease symptoms (day 14). This protocol demonstrated an in vivo
effect in EAE by decreasing the disease symptoms (Figure 1A).
Next, we determined the impact of icv MTX on non-
inflammatory demyelination, 16 mice were fed with cuprizone
for 4 weeks. Half of the animals received methotrexate intrac-
erebroventricularly (icv) dissolved in BrdU/PBS delivered by
osmotic pumps during the whole 4 weeks of cuprizone feeding
(Figures 2A,B). Control mice received BrdU dissolved in PBS.
Immunohistofluorescent analyses focused on the corpus callo-
sum were setup aiming to determine potential alterations caused
by methotrexate and to confirm the function of the osmotic
pumps by BrdU staining (shown in Figure 1B). After 4 weeks
of cuprizone feeding, mice were characterized by a reproducible
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FIGURE 1 | Osmotic pumps delivering MTX/PBS were functional.
(A) Active EAE was induced in 16 female C57Bl/6 mice. Half of the mice
received icv MTX (1.25µg per day) starting at day 14 after disease induction,
control mice received PBS instead. Error bars represent the standard error
of the mean. (B) Representative BrdU staining of brain sections of a mouse
that was treated with MTX/BrdU delivered by osmotic pumps for 4 weeks
showing that BrdU was delivered into the brain implying that the respective
animal also received methotrexate (200 × magnification).
demyelination and an increase in GFAP+ astrocytes and Iba1+
monocytic cells within the medial part of the corpus callosum
as compared to treatment naive mice. Icv MTX significantly
decreased the demyelination and accumulation of astrocytes in
the corpus callosum, while the number of Iba1+ monocytic cells
in the corpus callosumwas not significantly altered bymethotrex-
ate (Figures 2C,D).
High-dosage of methotrexate is known to cause leukoen-
cephalopathy, brain demyelination and astrocytosis (Gregorios
et al., 1989; Surtees et al., 1998). In order to exclude that
the dosage administered to cuprizone-fed mice had significant
detrimental effects, we treated naïve mice with icv MTX as
described before for 4 weeks without concomitant cuprizone
feeding. Immunohistofluorescent analyses of demyelination and
astrocyte accumulation in corpus callosum showed no demyeli-
nation and very low number of GFAP+ astrocytes. In this
experimental setup, icv MTX-treated mice were indistinguish-
able from PBS-treated control mice (Supplementary Figure 1)
suggesting that the chosen dosage of methotrexate did not have
significant side effects in murine brains.
We next showed that the effects of icv MTX on demyelina-
tion and astroglial activation are dependent on the timing of
MTX administration. We analyzed mice fed with cuprizone for
6 weeks that also received either methotrexate or PBS intrac-
erebroventricularly for the last 4 weeks (Figure 3A). In this
setting, methotrexate administration resulted in neither a signifi-
cant decrease of demyelination seen in the corpus callosum nor
an alteration of monocytic cell accumulation, but the number
of astrocytes accumulated in the corpus callosum was signif-
icantly lower in icv MTX treated mice than in control mice
(Figure 3B).
By using confocal microscopy, the influence of icv MTX on
astrocytes’ morphology was investigated. The majority of astro-
cytes found in the corpus callosum of PBS- and icv MTX treated
mice had a protoplasmic shape with only a very limited number
of processes (Supplementary Figure 2A) The average length of
astrocytic processes in PBS- and icv MTX-treated mice did not
differ significantly from each other (Supplementary Figure 2B).
Thus, icv MTX does not seem to have an obvious effect on the
morphology of astrocytes accumulating in the corpus callosum
during cuprizone-induced demyelination.
METHOTREXATE DOES NOT INTERFERE WITH REMYELINATION OF THE
CORPUS CALLOSUM
Remyelination is a complex process ensuring cellular integrity
after neuronal damage, as well as after primary loss of mature
oligodendrocytes. The cuprizone model is a suitable tool to study
the molecular mechanisms of remyelination in vivo (Armstrong
et al., 2006). To determine, if MTX interferes with remyelina-
tion, mice received methotrexate intracerebroventricularly after
the withdrawal of cuprizone from the diet (Figure 4A). In par-
ticular, mice were fed with cuprizone for 6 weeks followed by 4
weeks of feeding with normal chow without cuprizone to allow
the generation of oligodendrocytes. Eight mice received icv MTX
during these 4 weeks after cuprizone withdrawal; control mice
received PBS instead. Quantitative assessment of Iba1−, MBP−
and GFAP-stained brain slices revealed that the withdrawal of
cuprizone from the diet reduced the number of Iba1+ cells and
GFAP+ astrocyte numbers in the corpus callosum as well as the
amount of demyelination (data not shown). Mice treated with icv
MTX did not differ significantly from the control mice in any
of the aforementioned parameters (Figure 4B) suggesting that
MTX does not interfere with the spontaneous recovery after the
withdrawal of cuprizone.
The processes leading to remyelination of the corpus cal-
losum after 6 weeks of cuprizone feeding were reported to
be relatively fast (Stidworthy et al., 2003). To determine the
effects of icv MTX on remyelination in less favorable con-
ditions, we used 1 year old mice as remyelination is nat-
urally less robust during aging (Rist and Franklin, 2008).
The mice were sacrificed 2 weeks after cuprizone withdrawal
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FIGURE 2 | icv MTX administration modulates Cuprizone-induced
demyelination and astroglial activation. (A,B) Eight mice per group
were fed with cuprizone and received either 1.25µg/day methotrexate
dissolved in 10mg/mL BrdU/PBS intracerebroventricularly or just 10mg/mL
BrdU in PBS. After 4 weeks animals were sacrificed and the midline of the
corpus callosum was analyzed for pathological differences. (C)
Representative myelin (MBP), macrophage/microglial cell (IBA1), and
astrocyte (GFAP) staining of brain sections containing the corpus callosum
(200× magnification). (D) Quantitative analyses of demyelination and
numbers of macrophages/microglial cells and astrocytes in corpus
callosum. Twelve brains slices per mouse were analyzed. Error bars
represent standard deviations.
(Figure 4C). We found no significant differences in the number
of Iba1+ and GFAP cells and demyelination of the corpus cal-
losum between icv MTX and control treated mice (Figure 4D),
corroborating our hypothesis that MTX is not interfering
with repair processes in the cuprizone-induced demyelination
model.
POSSIBLE MECHANISM UNDERLYING THE EFFECT OF icv MTX
In order to elucidate the protective mechanism of methotrex-
ate, we analyzed the CSF cell transcriptome of eleven progressive
MS patients treated intrathecally with methotrexate and of fifteen
untreated progressive MS patients as described before (Muller
et al., 2012). By definition, untreated MS patients were not on any
disease modulating treatment for at least 1 year before the CSF
sample was drawn. 1596 probe sets were identified as differentially
expressed between ITMTX-treated MS patients and untreated
MS patients (Supplementary Table 1). The gene encoding for
the insulin-growth factor 1 (IGF1) was expressed in significantly
increased magnitude by CSF cells of patients treated intrathe-
cally with methotrexate compared to untreated MS patients
(Figure 5A, patients’ characteristics in Table 1). IGF1 is of high
interest, because it is known to protect oligodendrocytes from
cell death and prevents demyelination in the cuprizone model
(Mason et al., 2001). Additionally, it inhibits the activation of
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FIGURE 3 | Delayed onset of icv MTX administration does not prevent
demyelination but reduces astroglial activation. (A) Eight mice per group
were fed with cuprizone for a total of 6 weeks. For the last 4 weeks the mice
received additionally either 1.25µg/day methotrexate dissolved in 10mg/mL
BrdU/PBS intracerebroventricularly or just 10mg/mL BrdU in PBS.
(B) Quantitative analyses of demyelination and numbers of macrophages/
microglial cells and astrocytes in corpus callosum. Twelve brains slices per
mouse were analyzed. Error bars represent standard deviations.
FIGURE 4 | icv MTX administration does not interfere with repair
processes after Cuprizone withdrawal. (A) Eight mice per group were
fed with cuprizone for a total of 6 weeks. Afterwards mice received
either 1.25µg/day methotrexate dissolved in 10mg/mL BrdU/PBS
intracerebroventricularly or just 10mg/mL BrdU in PBS for another 4 weeks.
(B) Quantitative analyses of demyelination and numbers of macrophages/
microglial cells and astrocytes in corpus callosum. Twelve brains slices per
mouse were analyzed. Error bars represent standard deviations. (C) Eight 1
year old mice per group were fed with cuprizone for a total of 6 weeks.
Afterwards mice received either 1.25µg/day methotrexate dissolved in
10mg/mL BrdU/PBS intracerebroventricularly or just 10mg/mL BrdU in PBS for
another 2 weeks. (D) Quantitative analyses of demyelination and numbers of
macrophages/microglial cells and astrocytes in corpus callosum. Twelve brains
slices per mouse were analyzed. Error bars represent standard deviations.
astrocytes in vivo and in vitro (Fernandez et al., 2007; Bellini
et al., 2011). To confirm our finding of the increased expression
of IGF1 by CSF cells of ITMTX treated patients, we quantified
IGF1 protein in CSF samples derived from 19 untreated and
20-ITMTX-treated progressive MS patients. CSF levels of IGF1
protein were significantly higher in methotrexate-treated pro-
gressive MS patients than in untreated MS patients (Figure 5A,
patients’ characteristics in Table 1).
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Using a laser microdissection microscope, we isolated RNA
from the medial part of the corpus callosum of mice fed with
cuprizone for 4 weeks that received either methotrexate or PBS
intracerebroventricularly. IGF1 expression was determined by
RealTime PCR. We found a more than 150-fold upregulation of
IGF1 in cuprizone-fed mice compared to treatment naïve mice,
but no difference between icv MTX treated mice and control mice
(Figure 5B). Cuprizone feeding is already known to cause a very
strong upregulation of IGF1 (Komoly et al., 1992; Voss et al.,
2012). Hence, the general induction of IGF1 caused by cuprizone
may overshadow potential effects of icv MTX on IGF1 expression
in the brain of cuprizone-fed mice.
To corroborate that methotrexate influences IGF1 expression,
we incubated murine ES-OPCs in differentiation medium for
10 days with varying amounts of methotrexate and quantified
FIGURE 5 | Methotrexate modulates IGF1 expression in CNS and by
embryonic stem cells. (A) Left: The CSF cell transcriptome of 15 untreated
progressive MS and 11 ITMTX treated patients was analyzed by microarray
hybridization. Right: IGF1 levels were quantified in cell-free CSF samples
obtained from 19 control patients and 20 MS patients using a commercially
available IGF1 ELISA (RandD Systems). (B) Mice were fed with cuprizone
for 4 weeks. Additionally, they either received icv MTX or PBS. RNA was
isolated from the midline section of corpus callosum and IGF1 expression
determined by RealTime PCR. Bars represent IGF1 expression in respective
mouse group standardized to IGF1 expression in corpus callosum of
treatment naïve mice. (C) Methotrexate increases the expression of IGF1
by murine embryonic-derived oligodendroglial progenitor cells. 100,000
ES-OPCs cells incubated with different amounts of methotrexate diluted in
differentiation medium. After 10d the expression of IGF1 was determined
by RealTime-PCR (One-Way ANOVA). Error bars represent Standard
Deviations.
the expression of IGF1 by RealTime PCR. This experimental
setup resulted in a significant increase of IGF1 expression in
cells treated at a concentration of 10 ng/ml methotrexate or more
(Figure 5C). These results indicate that methotrexate increases
the production of the growth factor IGF1 in vivo (MS patients)
and in vitro (ES-OPCs). IGF1 upregulation possibly contributes
to the effects icv MTX has on demyelination and astroglial
activation.
DISCUSSION
Methotrexate is an antimetabolite that inhibits dihydrofolic acid
reductase. Dihydrofolate reduction to tetrahydrofolate is neces-
sary because it acts as a one-carbon group carrier in the syn-
thesis of purine nucleotides and thymidylate. Mechanistically,
methotrexate interferes with DNA synthesis and cellular repli-
cation, and thus inhibits cellular proliferation such as asso-
ciated with malignancy or generation of immune responses.
Methotrexate has a well-established protective effect in EAE,
an inflammatory animal model of MS (Rosenthale et al., 1969;
Levine and Sowinski, 1977). This protection relies most likely
on its well established immunosuppressive properties. Although
immunosuppressive agents are of limited therapeutic value in
progressive MS (Kieseier and Jeffery, 2010), intrathecal admin-
istration of low doses of methotrexate provided a benefit in
progressive MS patients resulting in a halt of the disability pro-
gression in 89% of 121 treated progressive MS patients (Sadiq
et al., 2010). This suggested that the mechanism of action of
ITMTX in progressive MS might not be solely mediated through
immune suppression.
To determine if methotrexate has an impact on neurodegener-
ative processes not primarily caused by inflammation, we inves-
tigated its use in the cuprizone-induced demyelination model
which is characterized by a primary oligodendrocyte apoptosis
independent of adaptive immunity (Arnett et al., 2001). This
model is frequently used to study processes leading to de- and
remyelination in the CNS in the absence of an autoimmune com-
ponent. It is debatable to what extent cuprizone-induced demyeli-
nation reflects human MS pathology. Primary oligodendrocyte
death and activation of astrocytes are hallmarks of the cuprizone
animal model. These pathological features are also characteristic
for human MS lesion formation. In addition, cuprizone-induced
oligodendrocyte-apoptosis may reflect pathological steps of newly
forming MS lesions in humans, because human type III and IV
MS lesions are partially mimicked by the cuprizone model (Kipp
et al., 2009; Zendedel et al., 2013).
Table 1 | Patients’ characteristics.
n Gender [F/M] Age ± SD [years] EDSS ± SD Disease duration ± SD [years] PPMS/SPMS
MICROARRAY STUDY
Untreated 15 12/3 52.6 ± 13 6.1 ± 1.9 18.5 ± 12 6/9
Itmtx treated 11 7/4 57.1 ± 12 6.7 ± 1.5 17.1 ± 9.7 4/7
IGF1 PROTEIN QUANTIFICATION IN CSF
Untreated 19 7/12 55.0 ± 9 3.5 ± 11 19.6 ± 10 4/15
Itmtx treated 20 5/15 51.4 ± 10 6.8 ± 1 21.7 ± 11 3/17
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We set up a series of experiments in which the icv delivery
of methotrexate started either at the onset of cuprizone feed-
ing, after 2 weeks of cuprizone feeding or upon withdrawal of
cuprizone. Mice received 1.25µg methotrexate per day delivered
by osmotic pumps, a dosage that was protective in active MOG-
induced EAE of C57Bl/6 mice and correlated with the low dose
ITMTX administration in progressive MS patients (Sadiq et al.,
2010).
We found thatMTX significantly reduced demyelination in the
corpus callosum only when administrated concurrently with the
cuprizone feeding, but not when started after 2 weeks of cupri-
zone feeding. This suggested that methotrexate influences the
onset of demyelination, but does not alter established demyeli-
nating processes. Methotrexate did not modulate the number of
Iba1+ macrophages/microglial cells in any of the experiments
significantly.
The most noticeable effect of MTX in the cuprizone model
was its inhibitory effect on the accumulation of reactive astro-
cytes within the corpus callosum. Diffuse activation of astro-
cytes with astrocytic proliferation and increased GFAP expression
is a characteristic pathologic feature of the cuprizone model.
Methotrexate decreased the number of reactive astrocytes accu-
mulating in the corpus callosum as determined by a significant
reduction in the number GFAP+ astrocytes in the corpus cal-
losum. This effect was seen in both, mice receiving icv MTX at
onset of cuprizone feeding and in mice treated with MTX 2 weeks
after initiation of cuprizone feeding. This data showed that icv
MTX inhibits the accumulation of reactive GFAP+ astrocytes in
the corpus callosum in this model. Although astroglial activation
is a prominent feature of MS, its exact role in the pathogene-
sis remains to be elucidated: Activated astrocytes contribute to
myelin breakdown by phagocytosis and to act as professional
antigen presenting cells (Lee et al., 1990), to secrete proinflam-
matory cyto- and chemokines (Tanuma et al., 2006; De Keyser
et al., 2008) and to interfere with myelin repair through astroglial
scar formation (Fawcett and Asher, 1999). However, selective
ablation of proliferating astrocytes in murine CNS worsened
the disease course of EAE due to increased CNS infiltration of
pathogenic immune cells (Voskuhl et al., 2009; Toft-Hansen et al.,
2011).
The specific role of astrocytes within progressive forms of
MS is hardly known: In chronic progressive MS astrocytic pro-
liferation is the hallmark feature of the characteristic sclerotic
plaques seen pathologically (Kuhlmann et al., 2008). In secondary
progressive MS patients, hyperactive astrocytes were found at
the rim of chronic demyelinating CNS lesions. These astrocytes
produced a variety of proinflammatory mediators like CCL2
and CXCL10. As these lesions did not include T-cells, it was
concluded that astrocytes may be key players driving the devel-
opment of chronic demyelinating CNS lesions (Tanuma et al.,
2006). Based on our findings in this cuprizone model one could
speculate that the deceleration of disability progression seen in
ITMTX treated progressive MS patients is partially due to an
inhibition of astroglial proliferation leading to a suppression of
proinflammatory chemokines and due to a reduction of scar
formation.
Demyelinated brain areas spontaneously remyelinate once
cuprizone is withdrawn from the diet. In the context of the
cuprizone model, remyelination is generally assumed to be per-
formed either by surviving oligodendrocytes and by maturation
of oligodendroglial progenitor cells into myelin-producing oligo-
dendrocytes (Kipp et al., 2009). Mice in which methotrexate
was administered after the withdrawal of cuprizone were indis-
tinguishable from control animals with regard to the degree of
myelination and to the number of macrophages/microglial cells
and astrocytes in the corpus callosum implying that methotrex-
ate does not affect repair processes in the cuprizone model. There
are several possible reasons for the lack of impact of icv MTX
on the remyelination of the corpus callosum in our experiments:
(1) The processes leading to the remyelination of demyelinated
brain regions after the withdrawal of cuprizone from the diet are
supposed to be very fast and reliable (Zendedel et al., 2013). We
studied methotrexate’s influence on remyelination under strin-
gent conditions by using mice with an age of 1 year at start of the
experiment and by analyzing them as soon as 2 weeks after cupri-
zone withdrawal. Nevertheless, it cannot be completely excluded
that we did not find any impact of icv MTX on repair processes
because the animals were sacrificed at time points at which the
repair was basically accomplished. (2) De- and remyelination
were quantified in this study by immunohistofluorescent-based
analyses of MBP in brain sections. MPB is a myelin component
that is re-expressed very early after the withdrawal of cupri-
zone from the diet (Lindner et al., 2008). It is possible that
analyses of MOG whose re-expression is considerably delayed
in comparison to MBP expression after cuprizone withdrawal
(Lindner et al., 2008) would have uncovered an impact of icv
MTX on remyelination of the corpus callosum. (3) Mice received
1.25µg of methotrexate per day. This low dose could have been
not enough to interfere with remyelination mediated by mature
oligodendrocytes that have survived the cuprizone treatment
and by differentiation of oligodendroglial progenitor cells into
mature oligodendrocytes. (4) Neural stem cells growing in a
folate-depleted culture or in the presence of methotrexate were
reported to differentiate preferentially into glial cells (Sato et al.,
2006). Thus, a possible repair-delaying property of methotrex-
ate within the recovery phase of the cuprizone-model could
have been counteracted by an enhancement of the differentia-
tion of neural stem cells into oligodendrocytes contributing to
remyelination.
Quantification of the CSF cell transcriptome of progressive
MS patients treated with intrathecal methotrexate revealed that
the expression of the growth factor IGF1 by CSF cells is higher
in ITMTX treated than in untreated progressive MS patients.
Increased IGF1 protein levels in CSF samples of ITMTX treated
patients compared to untreated patients substantiated this find-
ing. Unfortunately, we could not establish a direct link between
methotrexate and IGF1 in the cuprizone model as determined by
IGF1 expression in the corpus callosum of mice fed with cupri-
zone. This may be because IGF1 is more than 150-fold more
strongly expressed in cuprizone-treated mice than in treatment
naïve mice. The strong IGF1 upregulation that is generally seen
in the cuprizone model (Komoly et al., 1992) arguably overrides
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a putative induction of IGF1 by methotrexate. However, IGF1
expression was induced in murine ES-OPCs incubated in differ-
entiation medium supplemented with 10 ng/mL of methotrexate
or more. As IGF1 was described as an agent that protects oligo-
dendrocytes in the cuprizone model (Mason et al., 2001) and to
inhibit the activation of astrocytes in vitro and in vivo (Bellini
et al., 2011), the increased production of IGF1 in the CNS of
ITMTX treated patients plus the induction of IGF1 bymethotrex-
ate in oligodendroglial progenitor cell cultures provides indirect
evidence for a putative mechanism. Methotrexate administration
leads to an increase of IGF1 production in the CNS which may
favor the survival of oligodendrocytes and interfere with astroglial
activation.
Our studies establish a limited protective effect of methotrex-
ate on demyelination and a more pronounced inhibitory effect
on accumulation of reactive GFAP+ astrocytes in a non-
inflammatory demyelination model. This corroborates that the
beneficial impact of ITMTX in progressive MS patients reported
earlier (Sadiq et al., 2010) is not solely mediated by its anti-
inflammatory properties. Our work indicates that inhibition of
astroglial activation, possibly by increasing the production of the
growth factor IGF1 in the CNS may retard the generation of
astrocytic scars or sclerosis in MS lesions.
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Supplementary Figure 1 | A 4-week icv MTX administration does not have
detrimental side effects. (A) Experimental setup: Eight mice per group
were treated with icv MTX. Another eight mice received PBS
intraventricularly. (B) Quantitative analyses of numbers of GFAP+
astrocytes in corpus callosum. Ten brains slices per mouse were analyzed.
(C) Quantitative analyses of numbers of demyelination in corpus callosum.
Ten brains slices per mouse were analyzed. Error bars represent standard
deviations.
Supplementary Figure 2 | Methotrexate does not affect the length of
astroglial processes in the corpus callosum. (A) Top: Representative image
of corpus callosum of PBS- treated mouse (600× magnification). Bottom:
Representative image of corpus callosum of icv MTX-treated mouse
(600× magnification). (B) Quantitative analyses of the length of astroglial
processes. Six brains slices per mouse were analyzed. Error bars
represent standard deviations.
Supplementary Table 1 | Genes differentially expressed by CSF cells of
ITMTX treated MS patients compared to untreated MS patients. 794
probe sets were upregulated in ITMTX-treated MS patients and 802
downregulated (p ≤ 0.05).
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